Getting doctors to like biosimilars
This article was originally published in SRA
Executive Summary
Approving biosimilars is one thing; getting doctors to prescribe them is quite another. Usage of biosimilars is increasing in the EU, at least for some product classes, but it remains patchy, and while payers will welcome the cost savings biosimilars may bring, many physicians have yet to be convinced.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.